Fludarabine

Fludarabine, usually administered as fludarabine phosphate, is a synthetic purine nucleotide antimetabolite and an antineoplastic medicine used primarily in the treatment of B-cell chronic lymphocytic leukemia (CLL). It is a prodrug that is converted in the body to 2-fluoro-ara-A and then activated inside cells to 2-fluoro-ara-ATP. This active metabolite interferes with DNA synthesis by inhibiting enzymes including DNA polymerases and ribonucleotide reductase, which limits the ability of rapidly dividing malignant lymphocytes to grow and survive. Fludarabine is most commonly administered by intravenous infusion in current U.S. labeling, although oral formulations have also been developed and authorized in some countries. Its clinical importance comes from its established activity against B-cell CLL and its use as a component of combination chemotherapy regimens. Modern treatment has increasingly shifted toward targeted therapies, but fludarabine remains relevant in selected CLL treatment settings and in specific combination approaches. Because it can cause substantial bone-marrow suppression and prolonged immune suppression, treatment requires careful patient selection, blood-count monitoring, infection prevention, and assessment of kidney function.

Fludarabine was developed as a fluorinated purine nucleoside analogue derived from the adenine nucleoside analogue vidarabine. Early clinical studies demonstrated substantial cytoreductive activity in CLL, helping establish its role in patients with advanced or previously treated disease. The U.S. Food and Drug Administration first approved intravenous fludarabine phosphate in 1991 for adults with B-cell CLL whose disease had not responded to, or had progressed during, at least one standard alkylating-agent-containing regimen. In November 2024, FDA updated the labeling under Project Renewal, revising the indications and dosing information and incorporating major safety information into the Warnings and Precautions section. The current U.S. label includes use as a component of combination therapy for adult B-cell CLL and use in adults with B-cell CLL that has not responded to or has progressed during at least one alkylating-agent-containing regimen. Fludarabine-containing products have also been nationally authorized in several European countries, including oral formulations. Key clinical development included early single-agent studies in previously treated CLL and randomized comparisons with chlorambucil, followed by studies evaluating combinations such as fludarabine with cyclophosphamide and rituximab.

Fludarabine phosphate injection is approved in the United States for adults with B-cell chronic lymphocytic leukemia as a component of a combination regimen and for adults whose B-cell CLL has not responded to or has progressed during treatment with at least one alkylating-agent-containing regimen. The current U.S. prescribing information specifically includes combination treatment with cyclophosphamide and rituximab. Fludarabine has historically also been studied and used in other lymphoid malignancies and in combination chemotherapy, but such uses should be distinguished from currently approved indications and should follow applicable local regulatory guidance. Treatment selection depends on disease characteristics, previous therapy, patient fitness, renal function, blood counts, infection risk, and the availability of newer targeted treatments.

Fludarabine phosphate injection is administered intravenously under the supervision of healthcare professionals experienced in cancer chemotherapy. In the current U.S. labeling, the recommended single-agent regimen is 25 mg/m² administered intravenously over approximately 30 minutes on Days 1 through 5 of a 28-day treatment cycle. When used with cyclophosphamide and rituximab, fludarabine is administered at 25 mg/m² intravenously over approximately 30 minutes on Days 1 through 3 of each 28-day cycle, generally for six cycles, with the partner medicines administered according to their respective schedules. Dose reduction is required in patients with moderate renal impairment, and fludarabine should not be used in severe renal impairment according to the prescribing information. Treatment duration depends on the selected regimen, response, toxicity, blood counts, renal function, and overall clinical status. Complete blood counts, renal function, and clinical evidence of infection or other toxicity should be monitored throughout treatment.

Common side effects of fludarabine are largely related to its effects on the bone marrow and immune system. Frequently reported reactions include neutropenia, anemia, thrombocytopenia, fever, weakness, nausea, vomiting, diarrhea, cough, and infections. Reduced blood-cell production can increase susceptibility to bacterial, viral, or fungal infections and may require treatment interruption, supportive care, or additional monitoring. Fatigue and reduced appetite may also occur. The frequency and severity of adverse effects vary according to dose, treatment combination, previous therapies, age, kidney function, and general health. Patients receiving fludarabine should promptly report fever, signs of infection, unusual bleeding, severe weakness, or other concerning symptoms so that appropriate medical assessment can be provided.

Important serious risks include severe or prolonged myelosuppression, serious infections, opportunistic infections, severe immune suppression, autoimmune hemolytic anemia, and potentially serious central nervous system toxicity. Neurologic toxicity can include visual disturbances, confusion, agitation, seizures, encephalopathy, or other neurological changes and may be severe in some patients. Severe pulmonary toxicity has also been reported, particularly with inappropriate combinations involving pentostatin. Fludarabine can cause significant lymphocyte depletion and prolonged immunosuppression, increasing susceptibility to infections and affecting immune recovery. Serious delayed toxicity may occur even after treatment has ended. The current U.S. labeling removed the previous boxed warning in 2024 and incorporated key safety information into Warnings and Precautions, but careful monitoring remains essential. Fludarabine should be discontinued or interrupted when clinically significant toxicity develops, according to the treating physician's assessment.

Before treatment, clinicians should assess complete blood counts, renal function, liver function when clinically appropriate, infection status, previous therapies, and overall treatment fitness. Kidney function is particularly important because active fludarabine metabolites are substantially eliminated through the kidneys and dose adjustment is required with reduced creatinine clearance. Patients with significant immunosuppression require careful infection surveillance and appropriate preventive strategies. Live vaccines should generally be avoided during significant immunosuppression unless specifically recommended by a qualified healthcare professional. Fludarabine may interact clinically with other medicines or treatment approaches that increase myelosuppression or immunosuppression. Particular caution is required with pentostatin because of the risk of severe pulmonary toxicity when the two agents are combined. Concomitant treatment with other cytotoxic or immunosuppressive medicines should be carefully reviewed. Pregnancy should be avoided during treatment because fludarabine can cause fetal harm, and reproductive counselling may be appropriate.

Prescribers should confirm the indication, review previous CLL treatment, assess renal function and baseline blood counts, and evaluate infection risk before starting therapy. Dose selection should follow the applicable prescribing information and should be adjusted for renal impairment. During treatment, regular complete blood counts and clinical assessment for infection, bleeding, anemia, neurological symptoms, and other treatment-related toxicity are important. Pharmacists should verify dose calculations based on body-surface area, renal function, treatment cycle, and combination regimen, while ensuring appropriate preparation and intravenous administration according to product-specific handling requirements. Patients should be counselled to report fever, respiratory symptoms, unusual bleeding, severe fatigue, confusion, visual changes, seizures, or other neurological symptoms promptly. Coordination with infectious-disease, hematology, transfusion, and supportive-care services may be required in patients with significant cytopenias or prolonged immunosuppression.